Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, noninvasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
Bron:
http://www.medicalnewstoday.com/articles/191066.php
Zo ziet het apparaatje er uit:
Geweldige resultaten hoor; aanzienlijke verlenging van het leven (tot 28%) met hoogstwaarschijnlijk een veel hogere kwaliteit van het leven vergeleken met chemotherapie.
That which can be asserted without evidence can be dismissed without evidence.
